Array's pain drug clears PhII 'high hurdle' but QT signs raise some flags
This article was originally published in Scrip
Executive Summary
Array BioPharma's CEO was on the defensive on 1 August as the company's stock fell 15.2% on the company's news released after the market closed a day earlier that ARRY-797 provided statistically significant pain relief in a Phase II clinical trial; was just as effective as, but not superior to, oxycodone ER; and caused mild prolongations of the QTc interval in some patients, but not at levels that indicate cardiac arrhythmia.